 The US FDA granted it Breakthrough Therapy designation for glioblastoma in Feb 2015 meaning that it might be able to get approval sooner if it is effective.The phase II ACT III study reported encouraging results in June 2015.The ReACT clinical trial for glioblastoma reported encouraging results in 2015.